Sugi Predict

Sugi Predict / Compounds / SCHEMBL15056593

SCHEMBL15056593

SCHEMBL15056593

CCCCC(CCC)C(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.57
▸ CA2 P00918 1/20 0.57
▸ ALDH1A1 P00352 5/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ TSHR P16473 2/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CTSL P07711 1/20 0.50
▸ CTSS P25774 1/20 0.50
▸ CETP P11597 3/20 0.47
▸ CNR2 P34972 1/20 0.47
▸ PTGES O14684 3/20 0.46
▸ ALOX5 P09917 3/20 0.46
▸ PPARG P37231 2/20 0.46
▸ KMT2A Q03164 2/20 0.45
▸ SLC6A2 P23975 1/20 0.45
▸ SLC6A3 Q01959 1/20 0.45
▸ CTSK P43235 2/20 0.44
▸ MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27836703 0.98 CA1 (0.56) CA1CA2ALDH1A1MAPK1TDP1
Oxalic Acid SCHEMBL27851212 0.97 CA1 (0.55) CA1CA2ALDH1A1MAPK1TDP1
SCHEMBL28815597 0.97 ALDH1A1 (0.55) CA1CA2ALDH1A1MAPK1TDP1
SCHEMBL22501953 0.95 CA1 (0.56) CA1CA2ALDH1A1MAPK1TDP1
SCHEMBL27573384 0.94 CA1 (0.55) CA1CA2ALDH1A1MAPK1TDP1
SCHEMBL2837313 0.94 CA1 (0.55) CA1CA2ALDH1A1MAPK1TDP1
SCHEMBL28840647 0.94 CA1 (0.55) CA1CA2ALDH1A1MAPK1TDP1
SCHEMBL29080139 0.94 ALDH1A1 (0.52) CA1CA2ALDH1A1MAPK1TDP1
SCHEMBL11636918 0.94 CA1 (0.63) CA1CA2ALDH1A1MAPK1TDP1
Hydrochloric Acid SCHEMBL28380114 0.93 CA1 (0.53) CA1CA2ALDH1A1MAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112384509-B Furin inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2024-04-30 — — CN disclosed
CN-117769554-A Small molecule inhibitors of KRAS muteins 大鹏药品工业株式会社 2024-03-26 — — CN disclosed
CN-116981673-A Novel thiadiazolopyrimidinone derivatives 豪夫迈·罗氏有限公司 2023-10-31 — — CN disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 — — CN disclosed
CN-114585622-A Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents 诺华股份有限公司 2022-06-03 — — CN disclosed
CN-113874015-A Thienopyridine inhibitors of RIPK2 细胞基因公司 2021-12-31 — — CN disclosed
CN-113166174-A Free amino compounds for the treatment and prevention of bacterial infections 豪夫迈·罗氏有限公司 2021-07-23 — — CN disclosed
CN-111670187-B Beta-lactamase inhibitor and use thereof 苏州信诺维医药科技有限公司 2021-04-16 — — CN disclosed
CN-112384509-A Furin inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2021-02-19 — — CN disclosed
CN-111212644-B Amorphous solid dispersions of 5-aminopyrazole carboxamide compounds as BTK inhibitors 苏州信诺维医药科技有限公司 2021-01-15 — — CN disclosed
CN-111225669-A Crystalline form I of 5-aminopyrazole carboxamide compounds as BTK inhibitors 苏州信诺维医药科技有限公司 2020-06-02 — — CN disclosed
CN-111212644-A Amorphous solid dispersions of 5-aminopyrazole carboxamide compounds as BTK inhibitors 苏州信诺维医药科技有限公司 2020-05-29 — — CN disclosed
CN-106061971-B Pyrrolidinyl sulfone derivatives and their use as ROR gamma modulators 百时美施贵宝公司 2019-03-12 — — CN disclosed
EP-2794547-B1 PROCESS FOR THE PREPARATION OF ESTERS FROM FORMATES AND COMPOUNDS OLEFINICALLY UNSATURATED EVONIK DEGUSSA GMBH (DE) 2019-02-06 — — EP disclosed
US-9340485-B2 Process for preparing esters from formates and olefinically unsaturated compounds EVONIK INDUSTRIES AG (DE) 2016-05-17 — — US disclosed
EP-2794547-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS Evonik Industries AG (DE) 2014-10-29 — — EP disclosed
US-20140309435-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS EVONIK INDUSTRIES AG (DE) 2014-10-16 — — US disclosed
WO-2013092478-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS EVONIK INDUSTRIES AG (DE) 2013-06-27 — — WO disclosed
CN-102459272-A Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use GENENTECH INC 2012-05-16 — — CN disclosed
CN-102356085-A Imidazothiazole derivative having proline ring structure DAIICHI SANKYO CO LTD 2012-02-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309435-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS FDPS, ELOVL6, ELOVL3 CA1 3163/4885CA2 3961/4885ALDH1A1 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.